- Home
- RXO vs RARE Comparison
RXO vs RARE Comparison
Compare RXO & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXO
- RARE
- Stock Information
- Founded
- RXO 2022
- RARE 2010
- Country
- RXO United States
- RARE United States
- Employees
- RXO N/A
- RARE N/A
- Industry
- RXO
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- RXO
- RARE Health Care
- Exchange
- RXO Nasdaq
- RARE Nasdaq
- Market Cap
- RXO 2.9B
- RARE 2.6B
- IPO Year
- RXO N/A
- RARE 2014
- Fundamental
- Price
- RXO $15.44
- RARE $28.92
- Analyst Decision
- RXO Hold
- RARE Strong Buy
- Analyst Count
- RXO 17
- RARE 14
- Target Price
- RXO $19.73
- RARE $88.14
- AVG Volume (30 Days)
- RXO 1.5M
- RARE 3.4M
- Earning Date
- RXO 08-07-2025
- RARE 08-05-2025
- Dividend Yield
- RXO N/A
- RARE N/A
- EPS Growth
- RXO N/A
- RARE N/A
- EPS
- RXO N/A
- RARE N/A
- Revenue
- RXO $5,070,000,000.00
- RARE $590,689,000.00
- Revenue This Year
- RXO $34.70
- RARE $18.70
- Revenue Next Year
- RXO $7.16
- RARE $26.76
- P/E Ratio
- RXO N/A
- RARE N/A
- Revenue Growth
- RXO 32.38
- RARE 33.46
- 52 Week Low
- RXO $12.19
- RARE $25.81
- 52 Week High
- RXO $31.98
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- RXO 42.80
- RARE 43.19
- Support Level
- RXO $14.59
- RARE $26.85
- Resistance Level
- RXO $17.50
- RARE $28.48
- Average True Range (ATR)
- RXO 0.68
- RARE 1.16
- MACD
- RXO -0.20
- RARE 0.39
- Stochastic Oscillator
- RXO 29.21
- RARE 93.11
About RXO RXO Inc.
RXO Inc is a brokered transportation platform defined by cutting-edge technology and a nimble, asset-light business model, with the component being core truck brokerage business. Its operations also include three asset-light, brokered transportation services, all of which complement its truck brokerage business: managed transportation, last mile and freight forwarding. The company operates into one reportable segment. The operates within the transportation industry and in the same geography North America.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.